Multiple susceptibility enhancer variants increasing ADD3 expression predisposes to biliary atresia risk
Xinru Han, Haoyue Pei, Meirong Bai, Ying Zhou, Xun Chu
TL;DR
This study finds that multiple genetic variants in enhancer regions increase ADD3 expression, which contributes to the risk of biliary atresia in humans.
Contribution
Identifies multiple enhancer variants that upregulate ADD3 and functionally link them to biliary atresia pathogenesis.
Findings
28 SNPs clustered in 10 CREs showed enhancer activity, with three loci showing higher activity for risk haplotypes.
Zebrafish add3a overexpression or knockdown disrupted hepatobiliary development, mimicking BA pathology.
ADD3 overexpression in human BA livers supports a role for increased ADD3 in disease development.
Abstract
Non-syndromic biliary atresia (BA) is a multifactorial disorder with a poorly understood genetic basis. We previously identified 154 BA-associated SNPs spanning the ADD3 locus, which harbors the most strongly associated common variants in Asian populations. The susceptibility SNPs are in high linkage disequilibrium, but the causal variants remain unidentified. Using available databases, we predicted the regulatory potential of the 154 BA-associated SNPs. To functionally validate these findings, we assessed the enhancer activity of cis-regulatory elements (CREs) containing the risk variants using a dual-luciferase reporter assay. The role of ADD3 dysregulation in hepatobiliary development was investigated using zebrafish. The spatiotemporal expression pattern of the ADD3 ortholog in zebrafish embryos was mapped by in situ hybridization. Additionally, we performed mRNA overexpression and…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
FIGURE 1
FIGURE 2
FIGURE 3
FIGURE 4
FIGURE 5| Genomic elements | Start | End | Fragments lengths (bp) | SNPs | Non-risk haplotype | Risk haplotype |
|---|---|---|---|---|---|---|
| E1 | 109975641 | 109976391 | 751 | rs17095355- rs57440982 | CG | TA |
|
|
|
| 462 |
|
|
|
| E3 | 109982314 | 109983064 | 751 | rs11194940-rs141152014 | GCA | AC |
|
|
|
| 451 |
|
|
|
| E5 | 109984755 | 109985555 | 801 | rs12263915-rs72828241-rs11194941-rs75079039 | GTAT | CAGC |
| E6 | 109986233 | 109987083 | 851 | rs12244557-rs72828245 | TG | CT |
| E7 | 109990855 | 109991405 | 551 | rs3862006-rs2419313-rs72828247 | GGG | AAT |
| E8 | 109992254 | 109993604 | 1,351 | rs12265204-rs958086-rs56999964-rs7069789 | TGTC | CTCT |
| E9 | 109993914 | 109995064 | 1,151 | rs7073969-rs17126931 | CT | GC |
|
|
|
| 1,201 |
|
|
|
- —National Natural Science Foundation of China10.13039/501100001809
- —Natural Science Foundation of Shanghai Municipality10.13039/100007219
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPediatric Hepatobiliary Diseases and Treatments · Neonatal Health and Biochemistry · Congenital Ear and Nasal Anomalies
Introduction
1
Biliary atresia (BA) is a rare cholangiopathy that occurs in infants (Nizery et al., 2016). The incidence of BA varies between 1 in 10,000 in the US and 3.7 in 10,000 in parts of Asia (Hartley et al., 2009; Chiu et al., 2013; Nizery et al., 2016). Biliary atresia (BA) exists in two distinct forms: syndromic BA (∼10%) and non-syndromic BA (∼90%). Syndromic BA is characterized by the presence of various congenital anomalies, such as polysplenia, asplenia, heterotaxy syndrome, intestinal malrotation, and an interrupted inferior vena cava (IVC). This form is typically associated with Mendelian inheritance patterns. In contrast, non-syndromic BA presents as isolated atresia of the bile ducts without additional congenital abnormalities. It is considered a multifactorial disease, influenced by both genetic and environmental factors (Chu et al., 2012; Asai et al., 2015; Bezerra et al., 2018; Malik et al., 2020).
BA is a progressive fibroinflammatory disorder of infants involving the extrahepatic and intrahepatic bile ducts (Matthews et al., 2011; Cui et al., 2013; Tam et al., 2024). The diagnostic hallmark of BA lies in extrahepatic duct anomalies, yet the disease’s prognosis is predominantly governed by the secondary progressive intrahepatic cholangiopathy that develops even after successful portoenterostomy (Matthews et al., 2011). Recent genetic discoveries implicate primary cilia as central to the pathogenesis of BA (Berauer et al., 2019; Lam et al., 2021; Glessner et al., 2023; Lim et al., 2024), and structural defects in primary cilia of cholangiocytes throughout both intra- and extrahepatic bile ducts in BA liver tissues (Frassetto et al., 2018). The human cholangiocyte H69 cell line has been extensively used as a human in vitro model to study the pathogenic mechanisms involved in human BA (Coots et al., 2012; Clemente et al., 2015; Zhao et al., 2020). Zebrafish (Danio rerio) exhibit remarkable evolutionary conservation in hepatobiliary morphogenesis and organogenesis with mammals. The extrahepatic biliary anatomy in zebrafish exhibits high conservation with mammalian systems, including the presence of a gallbladder. By 5 days post-fertilization (dpf), the zebrafish liver demonstrates well-differentiated hepatocytes and cholangiocytes, along with an established intrahepatic ductal network. Zebrafish has been extensively utilized as an animal model in BA research (Matthews et al., 2011; Cui et al., 2013; Glessner et al., 2023).
Genome-wide association studies (GWAS) studies and following replication studies have revealed rs17095355 in the Adducin 3 (ADD3) gene region as the most strongly associated common variant with BA susceptibility in Chinese populations (Garcia-Barceló et al., 2010; Wang et al., 2018; Bai et al., 2020; Cui et al., 2023). This association was also validated in Caucasians (Tsai et al., 2014). Our previous GWAS study and imputation analysis identified rs17095355 and other 153 SNPs within this genomic region exhibiting genome-wide significant associations with BA in 336 nonsyndromic BA infants and 8,900 controls. All these 154 SNPs were in high LD (r^2^ > 0.9) with rs17095355 (Cui et al., 2023). Furtherly, we found risk allele of rs17095355 was correlated with increased ADD3 expression using eQTL analysis, and ADD3 was aberrantly deposit in the cholangiocytes and hepatocytes. Morpholino-mediated knockdown of add3a in zebrafish models resulted in hepatobiliary duct defects (Tang et al., 2016). However, the consequences of ADD3 overexpression in hepatobiliary remain to be elucidated.
It is now widely recognized that most human complex diseases result from the cumulative genetic effects of hundreds to thousands of variants scattered throughout the genome (Visscher et al., 2017). At each susceptibility locus, multiple variants show statistically significant associations with the phenotype, but it is a challenge to clarify the number of functionally independent contributors. This challenge arises because genetic variants in close proximity are often correlated due to linkage disequilibrium (LD), which reflects shared inheritance patterns rather than shared biological effects. As a result, statistical methods alone cannot reliably distinguish causal variants from nonfunctional ones that are merely correlated through LD. Therefore, experimental validation by perturbing candidate variants and assessing their phenotypic impact is essential to resolve true causal relationships (Chatterjee et al., 2016; Chatterjee et al., 2021).
The ADD3 variation was identified as the most strongly associated BA susceptibility locus. However, several major questions remain unanswered. First, because multiple SNPs in high LD were associated with BA risk, which SNPs affect ADD3 expression? Second, do these disease-associated alleles increase BA susceptibility by upregulating or downregulating ADD3 expression? Third, does upregulation of ADD3 impair the structure and function of hepatobiliary system? In the current study, we searched the available databases to predict the potential functional consequences for the 154 associated SNPs. Then, we evaluated the allele specific expression of the candidate SNPs using dual-luciferase reporter assays. Finally, the zebrafish model was used to assess the impact of knockdown and overexpression of ADD3 ortholog on the development of hepatobiliary duct and gallbladder.
Materials and methods
2
Screen for cis-regulatory element variants
2.1
We interrogated the 154 BA-associated SNPs against regulatory annotations from both ENCODE and HaploReg databases. SNPs overlapping histone marks, DNase I hypersensitive sites, protein binding regions, or transcription factor motifs were predicted to reside within cis-regulatory elements (CREs). We performed systematic screening of the SEdb 3.0 database to identify super enhancers that co-localize with experimentally validated enhancer-active CREs.
Cell culture
2.2
Human H69 cholangiocytes were cultured at 37 °C with 5% CO_2_ in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, California, United States) and 100 IU/mL penicillin (Gibco, California, United States).
Dual-luciferase report assay
2.3
DNA fragments flanking the 28 candidate SNPs were cloned into the pGL4.23 luciferase vector (Promega, United States). H69 cells in 24-well plates (Corning, United States) were co-transfected with either the pGL4.23 constructs or the empty pGL4.23 vector, along with the Renilla luciferase control vector, using Lipofectamine 8000 (Beyotime, Shanghai, China). Twenty-four hours post-transfection, luminescence was measured with the Dual-Luciferase Reporter Assay System (Yeasen, Shanghai, China) on a Synergy™ H1 Hybrid Multimode Microplate Reader (BioTek, United States). Firefly luciferase activity was normalized to Renilla luciferase activity for data analysis.
Zebrafish lines
2.4
All zebrafish experiments were performed using wild-type AB-strain reared at Xinhua Hospital. Procedures were conducted in accordance with institutional guidelines and approved by the Xinhua Hospital Animal Care and Use Committee (XHEC-WSJSW-2018-029).
Real-time polymerase chain reaction (RT-PCR)
2.5
Total RNA was extracted from 5 h post-fertilization (hpf) embryos using TRIzol reagent (Invitrogen, United States) in accordance with the manufacturer’s instructions. RT-PCR was performed using SYBR Green Master Mix with fluorescent labeling (Applied Biosystems, Cat#A25742, United States) on a QuantStudio Dx Real-Time PCR Instrument (Applied Biosystems, CA, United States). The 18S ribosomal RNA (18S rRNA) gene served as the normalization control. All assays were conducted in triplicate. Relative gene expression levels were calculated using the ΔΔ^CT^ method, expressed as RQ values (RQ = 2^−ΔΔCT^). Primer sequences used for RT-PCR are listed in (Supplementary Table S1).
Whole-mount in situ hybridization (WISH)
2.6
First-strand cDNA was then synthesized from 1 μg total RNA using PrimeScript RT Master Mix (Takara, Japan). PCR primers were designed to generate a 456-bp antisense riboprobe targeting zebrafish add3a (Supplementary Table S2). The PCR products were subsequently cloned into the pGEM-T Easy Vector (Promega, WI, United States). Digoxigenin-labeled antisense and sense RNA probes were then synthesized using the linearized plasmid templates (Roche Applied Science, Penzberg, Germany).
At 24 hpf, larvae were maintained in 0.003% 1-phenyl-2-thiourea (PTU; Sigma-Aldrich) to inhibit melanin formation. For fixation, zebrafish embryos were incubated overnight at 4 °C in 4% paraformaldehyde (Sangon, Shanghai, China), followed by dehydration and storage in 100% methanol (MeOH) at −20 °C for ≥2 h prior to processing. The chorions of larvae were manually removed under a stereomicroscope using fine forceps. Embryos >1 dpf were permeabilized with proteinase K (10 μg/mL) for 15–30 min (RT) to facilitate probe penetration.
Following prehybridization (2–4 h, 60 °C), embryos were hybridized overnight with 600 ng antisense probe at 60 °C. After blocking (3 h, RT), samples were incubated overnight at 4 °C with anti-DIG-AP antibody (1:5000; Roche). Signal detection was performed using BM Purple AP substrate (Roche) with subsequent imaging on a Nikon SMZ25 stereomicroscope (Chiyoda, Japan).
Morpholino antisense oligonucleotide design and injection
2.7
Morpholino antisense oligonucleotides (MOs) targeting add3a were designed and synthesized by GeneTools, LLC. A standard MO was used as the negative control. Translation-blocking (TMO) and splice-blocking (SMO) were designed to inhibit the 5′translational start site and a splice acceptor site respectively (Supplementary Table S3). Knockdown of add3a were mediated by injecting SMO and TMO into the yolk of 1 to 4-cell stage embryos. MOs were diluted to 0.25 mM in sterile double distilled water and approximate 2 nL/embryo MO was injected. To validate the efficiency of add3a splice-blocking morpholino (SMO), zebrafish embryos at 3 dpf were collected after microinjection. Total RNA was extracted, reverse-transcribed into cDNA, and analyzed by RT-PCR followed by gel electrophoresis to detect aberrant splicing products indicative of successful knockdown. To validate TMO efficacy, we PCR-amplified a 118-bp fragment encompassing the TMO target sequence from zebrafish cDNA and subcloned it into the pEGFP-N1 plasmid. Fluorescence attenuation following co-injection of TMO with this reporter construct confirmed successful translational inhibition. Primers are listed in Supplementary Table S4.
In vitro synthesis of mRNA and mRNA injection
2.8
Using cDNA from 5 dpf zebrafish eggs as the template, the full-length coding sequence of add3a was amplified by RT-PCR with the high-fidelity enzyme. Primers are listed in Supplementary Table S5. The full-length add3a fragment was purified by gel extraction. Homologous sequences corresponding to the linearized vector ends and restriction enzyme sites were added to the 5′ends of the primers. The pCS2+ empty vector was linearized by digestion with EcoR I. The purified PCR product was then cloned into the linearized pCS2+ vector in the SP6 forward orientation using the Hieff Clone Plus One Step Cloning Kit (YEASEN, China). The plasmid containing add3a was linearized with KpnI and used as a template for in vitro transcription to generate full-length mRNA. Capped mRNA was transcribed using the mMESSAGE mMACHINE Kit with SP6 polymerase (Thermo, United States). Embryonic microinjection 100 pg add3a mRNA was performed into one-to four-cell embryos.
PED6 treatment
2.9
PED6 is a fluorogenic substrate for phospholipase A2. It is metabolized in the liver and excreted into bile, accumulating in the gallbladder. To directly visualize the gallbladder, 5 dpf zebrafish embryos were incubated with 0.1 mg/mL PED-6 (Invitrogen, United States) for over 2 hours. Images from the PED-6 assay were acquired using a stereo fluorescence microscope (Leica, German) (So et al., 2018). Embryos in each group were categorized as “normal”, “faint”, or “absent” based on gallbladder size and the intensity of PED-6 fluorescence (Cui et al., 2013).
Biliary architecture analysis by whole-mount immunofluorescence
2.10
Zebrafish larvae at 5 dpf were fixed in methanol:DMSO (4:1) for 2 h at room temperature, followed by post-fixation in 100% ice-cold methanol for long-term storage. After rehydration through a graded methanol series in PBSX (PBS containing 0.5% Triton X-100), the larval epidermis was carefully removed to enhance antibody penetration. Samples were blocked for 1 h in 10% bovine serum albumin (BSA) with 0.5% Triton X-100 at room temperature.
Primary immunostaining was performed using mouse anti-Keratin 18 monoclonal antibody (Ks18.04; PROGEN, Cat#61028; 1:100 dilution in blocking buffer) overnight at 4 °C with gentle agitation. After extensive washing with PBSX, specimens were incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody (YEASEN, Cat#33206ES60; 1:500 dilution) overnight at 4 °C.
Immunostained larvae were mounted in glycerol and imaged using a Leica TCS SP8 confocal microscope (Leica Microsystems, Germany). Images were processed using Adobe Photoshop CS6, and quantitative morphometric analyses (intrahepatic duct length and gallbladder area) were performed using ImageJ software (NIH).
Statistical analysis
2.11
Statistical analyses were performed using GraphPad Prism software. The data presented as mean ± SEM. Normality was assessed using the Shapiro-Wilk or Kolmogorov-Smirnov test (as appropriate), followed by Levene’s test for homogeneity of variance when parametric assumptions were met. Normally distributed data were analyzed using either a two-tailed Student’s t-test (for two-group comparisons) or one-way ANOVA (for multiple groups). The categorical data were analyzed using the χ^2^ test. A two-sided P-value < 0.05 was considered statistically significant for all analyses.
Results
3
Screen for cis-regulatory element variants
3.1
In a GWAS of BA susceptibility in Chinese individuals, we identified 154 SNPs reaching genome-wide significance (P < 5 × 10^−8^), including rs17095355 as the lead variant. All of these SNPs lie in the 5′upstream intergenic region or introns of ADD3 and are in high LD with rs17095355 (r^2^ > 0.9). eQTL analysis revealed that the risk allele of rs17095355 correlated with increased ADD3 expression. To identify causal variants among the 154 BA-associated SNPs, we screened for SNPs located within cis-regulatory elements (CREs) by querying data from ENCODE and HaploReg. This analysis revealed 28 SNPs across 10 distinct CREs (Figure 1), with spatially clustered SNPs co-localizing within the same CREs (Figure 1A). Among the 28 associated SNPs, 20 were located in regions containing histone marks characteristic for enhancers, 19 resided in DNaseI hypersensitive sites, seven overlapped transcription factor binding sites, and 24 were predicted to alter transcription factor motifs (Supplementary Tables S6, S7).
Genomic Map and Enhancer variants within the ADD3 Locus. (A) Genomic locations of 28 BA-associated SNPs within predicted enhancer regions, marked by DNase I hypersensitivity, H3K4me1, and H3K27ac, and overlapping with predicted transcription factor binding sites. (B) Distribution of 28 BA-associated SNPs across 10 predicted enhancer segments. (C) Allele-specific luciferase reporter assays for 10 enhance elements. Eight elements demonstrated enhancer activity compared to promoter-only control, with four showing significant allelic differences (t-test). Error bars represent standard deviation (SD) of four biological replicates. (D) Flowchart outlining the approach for identifying causal variants among 154 BA-associated SNPs.
Functional tests of enhancer activity
3.2
We conducted in vitro functional tests of enhancer activity for the 10 CREs harboring 28 susceptibility SNPs. We cloned DNA fragments centered on the variants into the PGL4.23 luciferase vector and transfected them into Human H69 cholangiocytes (Table 1; Figure 1A). Totally, 10 elements were tested (Figure 1B; Table 1). Our results revealed that eight elements (E1, E2, E3, E4, E7, E8, E9 and E10) demonstrated significant enhancer activity (P < 0.0001 and > 2-fold increase in reporter activity compared to promoter-only control vector) and four elements (E2, E4, E9 and E10) showed allele-specific reporter activity differences (Figure 1C). Among the latter, 75% of risk haplotypes (E2, E4 and E10) exhibited higher enhancer activity than their non-risk counterparts (Figure 1D). Although the E1 region containing lead SNP rs17095355 showed strong enhancer activity in our assays, the similar activity levels between risk and non-risk haplotypes (P = 0.13) imply that this SNP might not be the functional variant responsible for the observed genetic association.
Super-enhancers (SEs) are clusters composed of multiple transcriptional enhancers that coordinately regulate gene expression (Wang et al., 2022). In this region, eight elements exhibiting enhancer activity were identified, suggesting that the locus may function as a SE. To explore this further, we queried SEdb 3.0. The results indicated this region acts as a SE across a broad range of tissues and cell types, including the liver tissue (Supplementary Table S8) (Wang et al., 2022).
At E2, the risk haplotype CdeletionT (rs9630101-rs35533450-rs9630102) showed 6.1-fold increased luciferase activity compared to the control (basal promoter), and 3.1-fold higher activity compared to the non-risk haplotype (P = 1.9 × 10^−5^). At E4, the risk haplotype TA (rs12240333-rs61614979) showed 8.2-fold increased luciferase activity compared to the control (basal promoter) and 2.7-fold higher activity compared to the non-risk haplotype (P = 1.4 × 10^−6^). At E10, the risk haplotype TTTT (rs2122517-rs7904096-rs7079713-rs7083619) showed 8.7-fold increased luciferase activity compared to the control (basal promoter) and 2.4-fold higher activity compared to the non-risk haplotype (P = 2.3 × 10^−5^). Our previous study found that the risk alleles were associated with increased expression of ADD3, which is overexpressed in BA cholangiocytes and hepatocytes (Cui et al., 2023). Taken together with the present results, these findings suggest that BA-associated risk alleles contributed to BA pathogenesis by upregulating ADD3 expression.
Spatiotemporal expression of add3a in developing zebrafish embryos
3.3
To explore the role of ADD3 dysregulation in hepatobiliary development, we employed zebrafish as a model system. We firstly used RT-PCR and WISH experiments to instigate whether add3a, the ortholog of human ADD3 in zebrafish, was expressed in the developing liver of zebrafish. The qPCR results showed that the expression of add3a was present at 4 hpf, gradually increases until it peaks at 48 hpf, after which its expression slightly decreases and stabilizes (Figure 2A). The WISH results showed that add3a was mainly expressed in the head at 24-96 hpf, and was observed to be expressed in the liver at 72 hpf and 96 hpf (Figure 2B). These observed expression patterns strongly indicate the potential involvement of add3a in the development of hepatobiliary system.
Spatiotemporal expression patterns of add3a in zebrafish embryos. (A) Relative mRNA level of add3a in zebrafsih embryos at 4, 8, 12, 24, 48, 72, 96 and 120 hpf; The data are shown as the mean ± SEM. (B) Spatial expression patterns of add3a was detected by WISH at 24, 48, 72 and 96 hpf zebrafish embryos. Black arrowheads marked livers. Scalebar = 100 μm hpf, hour postfertilization; SEM, Standard error of the mean; WISH, whole-mount insituhybridization.
Both overexpression and knockdown of add3a impair hepatobiliary development
3.4
Following our add3a expression analysis, we overexpressed add3a in zebrafish to model the upregulation effects observed in BA livers on hepatobiliary function and structure. Previous study reported that knockdown of add3a produced intrahepatic defects and impaired biliary function; therefore, we also performed a knockdown analysis for comparison (Tang et al., 2016).
We overexpressed add3a by injecting its mRNA into zebrafish embryos to assess its effect on hepatobiliary development. RT-PCR showed a marked upregulation of add3a expression (Figure 3A). PED6 accumulation in the gallbladder was significantly reduced in add3a mRNA–injected larvae relative to controls (Figures 4A,B), implying impaired hepatobiliary function (Cui et al., 2013). We examined the liver and gallbladder by cytokeratin 18 immunofluorescence staining. Biliary abnormalities were evident in the add3a-overexpressing larvae compared with control larvae (Figures 4C,D). Relative to control MO larvae, add3a-overexpressing larvae exhibited reduced intrahepatic duct density and a decreased number of interconnecting ducts and terminal ductules (Figure 4C). Furthermore, the gallbladders were smaller, with significantly fewer cells and a smaller average cell area in the add3a-overexpressing larvae than in controls (Figure 4D).
Validation of add3a upregulation via mRNA overexpression and knockdown using MOs. (A) RT-PCR confirmed successful overexpression of add3a, demonstrated by an increased level of add3a mRNA. (B) The target sites of add3a-SBMO and add3a-TBMO are shown. (C) RT-PCR and gel electrophoresis verified the effectiveness of add3a-SBMO, indicated by a decrease in band intensity. (D) The diminished fluorescence of PEGFP-N1 following co-injection with add3a-TBMO confirmed the effectiveness of add3a-TBMO (n = 20).
*Knockdown or overexpression of add3a induces biliary dysfunction in zebrafish. (A) Lateral view of 5 dpf zebrafish larvae after ingestion of PED-6. The gallbladders of larvae injected with add3a mRNA or MOs were smaller compared to control embryos. (B) Quantitative analysis showed that the accumulation of PED-6 in the gallbladders of mRNA-injected larvae and morphants were significantly reduced compared to control larvae. Scale bar = 100 μm. Chi-square test was used. *P < 0.05; **P < 0.01; **P < 0.001. (C) Confocal projection of 5 dpf larvae stained for cytokeratin 18, comparing control larvae, mRNA-injected larvae, and add3a morphants. The intrahepatic bile ducts in both mRNA-injected larvae and add3a morphants appeared sparser than in controls. n = 10 for each group. (D) Confocal projection of 5 dpf larvae stained for cytokeratin 18, showing that the gallbladders of both mRNA-injected larvae and add3a morphants were smaller than those of controls. n = 10 for each group. Gallbladder cells are indicated by white dots.
We performed MO–mediated knockdown to reduce add3a expression, using a SBMO and a TBMO. The SBMO targets the exon 1 splice acceptor site of add3a, while the TBMO targets the translation start region in the first exon (Figure 3B). We confirmed MO efficacy: SBMO injection reduced band brightness on RT-PCR (Figure 3C), and TBMO injection abolished PEGFP-N1 plasmid fluorescence (Figure 3D). Co-injection of SBMO with overexpression constructs yielded higher band intensity than SBMO alone (Figure 3B). Rescue experiments with co-injection of full-length add3a overexpression mRNA alongside SBMO or TBMO partially restored the MO-induced phenotypes (Figure 4B), supporting MO specificity. SBMO- and TBMO-mediated knockdown reduced PED6 accumulation in the gallbladder and impaired intrahepatic ductal development as well as gallbladder morphology (Figures 4A–D).
Overall, our findings indicate that add3a is essential for normal hepatobiliary development in zebrafish. Hepatobiliary development is highly sensitive to add3a levels, as both overexpression and knockdown cause disruption, indicating precise dosage control is essential. Collectively, these in vivo data support the notion that BA-associated risk alleles contribute to BA pathogenesis by upregulating ADD3 expression.
Discussion
4
Our previous study identified 154 non-coding SNPs in high LD associated with BA risk. In the current study, bioinformatics prediction revealed 28 SNPs lying in the enhancer region and disturbing transcriptional factors binding sites. Eight SNPs located in three regions showed enhancer activity and risk haplotypes exhibited higher enhancer activity than their non-risk counterparts. These results suggested multiple disease-associated SNPs might synergistically enhance ADD3 expression levels. Overexpression ADD3 orthologue in zebrafish models caused impaired hepatobiliary function and structure, which mimic the phenotypes of BA in human.
Our current data from human genetics and in vitro functional tests of enhancer activity identified eight distinct CREs around ADD3 with common sequence variants that are associated with BA. But only four CREs show allelic specific difference in enhancer activity, and the risk alleles of three showed upregulation activity. These CREs might control ADD3 expression within a topologically associating domain (TAD). It is reasonable to speculate that they act synergistically and cluster together as super-enhancers, thereby significantly amplifying ADD3 expression. These findings align with observations from our prior study and other group, indicating that ADD3 is over expressed in BA cholangiocytes and hepatocytes (Ye et al., 2017; Cui et al., 2023). Of note, the risk haplotype GC (rs7073969-rs17126931) at E9 showed 3.1-fold increased luciferase activity compared to the control (basal promoter), while 1.6-fold lower activity compared to the non-risk haplotype (P = 0.004). The risk haplotypes at three CREs (E2, E4, and E10) consistently demonstrated increased luciferase activity, whereas the risk haplotype at E9 showed reduced activity relative to its non-risk counterpart. This differential effect could potentially be explained by two non-exclusive mechanisms: (1) Tissue-specific regulatory context - The E9 locus may interact with biliary cell-specific repressive factors that are absent in our heterologous reporter assay system; and (2) Transcriptional resource competition - The GC risk haplotype might compete with other enhancer elements for limiting transcriptional machinery components, resulting in attenuated net activity. Taken together, the risk SNPs synergistically upregulate ADD3 expression, thereby contributing to BA pathogenesis.
ADD3 encodes adducin 3. As depicted in Figure 5, adducins are tetrameric proteins composed of α (ADD1)/β (ADD2) or α/γ (ADD3) heterodimers. In most tissues, including the liver and biliary system, ADD1 heterodimerizes with ADD3. As an actin-binding protein (Figures 5A,E), Adducin plays a crucial role in regulating filament dynamics by capping the fast-growing ends of actin filaments and facilitating their bundling (Figures 5A,B) (Moztarzadeh et al., 2022). Importantly, Adducin is a membrane-skeletal protein involved in the structural support of the cell membrane by linking the spectrin-actin network (Figure 5C). By stabilizing the connection between spectrin and actin, Adducin helps maintains cell shape and prevent mechanical instabilities in the cell membrane. Our results in zebrafish found that both knockdown and overexpression of ADD3 orthologue resulted in abnormal gallbladder cells and sparse intrahepatic bile ducts. These findings implicate ADD3 dysregulation results in altered cell shape and participates in the occurrence of BA (Figure 5E).
A schematic diagram illustrating the function of ADD3 and the molecular mechanisms by which ADD3 is involved in BA pathogenesis. (A) The actin cytoskeleton is composed of actin filaments polymerized from monomeric G-actin. Adducin, typically a heterodimer of ADD1 and ADD3, caps the barbed ends of actin filaments to inhibit further polymerization. (B) Adducins facilitate bundling of actin filaments. (C) Adducins recruit and crosslink spectrin at the filament termini, organizing the spectrin-actin network. (D) The cytoplasmic actin-adducin cytoskeleton regulates centrosome migration and docking to the apical plasma membrane, facilitates vesicle transport to the centriole, and mediates the entry of signal receptors into the ciliary membrane. Additionally, F-actin is a component of the axonemal cytoskeleton, positioned between alpha-tubulin singlets and located between microtubules and the ciliary membrane. (E) Adducins play a crucial role in maintaining cell shape, stabilizing junction complexes, and regulating ciliogenesis and ciliary function (left panel). Dysregulation of Adducin alters cell shape, impairs the stability of tight junctions and cell barrier integrity, disrupts cilia structure and function, and thereby contributes to BA pathogenesis (right panel).
Spectrin-adducin-mediated membrane attachments of the perijunctional F-actin belt helps stabilize junctional structures by confining adherens junction (AJ)/tight junction (TJ) proteins at the apical cell surface and restricting their diffusion within the plasma membrane (Figure 5E) (Naydenov and Ivanov, 2011; Kugelmann et al., 2015). Depletion of adducin directly disrupts the formation of epithelial adherens junctions (AJs), which subsequently hinders the reassembly of tight junctions (TJs) (Moztarzadeh et al., 2022). Defects were observed in the assembly of cell junctions and polarity complexes in both cholangiocytes and hepatocytes in BA livers (Zhou et al., 2021; Amarachintha et al., 2022). These lines of evidence suggest ADD3 dysregulation impair junction complex, thereby contributing to the pathogenesis of BA (Figure 5E).
Actin also plays a critical role in ciliogenesis and cilia maintenance in both the cytoplasm and the ciliary compartment (Hufft-Martinez et al., 2024). Cytoplasmic actin-adducin cytoskeleton controls centrosome migration and docking to the apical plasma membrane, vesicle transport to the centriole, and the entry of signal receptors within the ciliary membrane, thus regulating signaling (Figure 5D) (Francis et al., 2011; Yadav et al., 2016). F-actin also localize in primary cilia (Kiesel et al., 2020). It is a component of the axonemal cytoskeleton, and presents between alpha tubulin singlets and between the microtubules and ciliary membrane (Kiesel et al., 2020). It forms the site of ectocytosis, and regulates ciliary-mediated signaling. Actin is also found in the ciliary membrane, and thereby regulates ciliary membrane permeability (Zuo et al., 2019). Mutations in genes that affect the structure and function of cilia cause a group of inherited disorders called ciliopathies. Rare deleterious mutations are present in a broad range of liver-expressed ciliary genes in BA patients, implying BA as a type of ciliopathy (Lam et al., 2021). Since Adducin plays an important role in actin polymerization and cytoskeleton dynamic stability, we believe that ADD3 dysregulation directly impairs the ciliary homeostasis of cholangiocytes, subsequently influences BA pathogenesis (Figure 5E).
In conclusion, we identified multiple associated SNPs within cis-regulatory elements exhibiting enhancer activity. The risk alleles were associated with increased ADD3 expression. Both upregulation and downregulation of ADD3 disrupting hepatobiliary structure and function. The upregulation of ADD3 driven by synergistic effects of these associated SNPs contributes to the pathogenesis of BA.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Amarachintha S. P. Mourya R. Ayabe H. Yang L. Luo Z. Li X. (2022). Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia. Hepatology 75, 89–103. 10.1002/hep.32107 34392560 PMC 9983428 · doi ↗ · pubmed ↗
- 2Asai A. Miethke A. Bezerra J. A. (2015). Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes. Nat. Rev. Gastroenterol. Hepatol. 12, 342–352. 10.1038/nrgastro.2015.74 26008129 PMC 4877133 · doi ↗ · pubmed ↗
- 3Bai M. R. Niu W. B. Zhou Y. Gong Y. M. Lu Y. J. Yu X. X. (2020). Association of common variation in ADD 3 and GPC 1 with biliary atresia susceptibility. Aging (Albany NY) 12, 7163–7182. 10.18632/aging.103067 32315284 PMC 7202506 · doi ↗ · pubmed ↗
- 4Berauer J. P. Mezina A. I. Okou D. T. Sabo A. Muzny D. M. Gibbs R. A. (2019). Identification of polycystic kidney disease 1 like 1 gene variants in children with biliary Atresia splenic malformation syndrome. Hepatology 70, 899–910. 10.1002/hep.30515 30664273 PMC 6642859 · doi ↗ · pubmed ↗
- 5Bezerra J. A. Wells R. G. Mack C. L. Karpen S. J. Hoofnagle J. H. Doo E. (2018). Biliary atresia: clinical and research challenges for the twenty-first century. Hepatology 68, 1163–1173. 10.1002/hep.29905 29604222 PMC 6167205 · doi ↗ · pubmed ↗
- 6Chatterjee S. Kapoor A. Akiyama J. A. Auer D. R. Lee D. Gabriel S. (2016). Enhancer variants synergistically drive dysfunction of a gene regulatory network in Hirschsprung disease. Cell 167, 355–368.e 310. 10.1016/j.cell.2016.09.005 27693352 PMC 5113733 · doi ↗ · pubmed ↗
- 7Chatterjee S. Karasaki K. M. Fries L. E. Kapoor A. Chakravarti A. (2021). A multi-enhancer RET regulatory code is disrupted in Hirschsprung disease. Genome Res. 31, 2199–2208. 10.1101/gr.275667.121 34782358 PMC 8647834 · doi ↗ · pubmed ↗
- 8Chiu C. Y. Chen P. H. Chan C. F. Chang M. H. Wu T. C. Taiwan Infant Stool Color Card Study Group (2013). Biliary atresia in preterm infants in Taiwan: a nationwide survey. J. Pediatr. 163, 100–103.e 101. 10.1016/j.jpeds.2012.12.085 23414661 · doi ↗ · pubmed ↗